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۶Ԫ˕ ѿԮࡏࡶ ߇ˈ ݤ࢖ବы ଝࡢ˕ࢽ, ࢇࢿ ٸԻܕ ֻҘ ˕ࢽࡶ 
ց৔ֲ ए΢ ݤɾࡶ ѸѪ߅مТЬ. ঈࡸ ؃ی˕ࢽ߾ ؈ࡶ ҡң ΤԻٕਫ਼ 
ए̖ ࢇ ܻɾ̧एࢂ ݤɾࡵ ࢵ߾ʯЕ ଝחࢂ ̟ ڸ ߅ТԂ ۢࢠࢂ 
ݤɾࢇ߹ˈ ʃیଞ ۓࢇ߹ݡТЬ. ̐ ݤɾ Ѱ߇ ࠔ߾۰ Ѧ࣯ࠪݦ քࡵ 
ٗҚࢇ ߅Т߹Ьִ ߭ӊʯ ए̖ ࢇ ܻɾࢇ ࢑߹ࡶए ۘۘࢇ ɼए ߉ݡТЬ. 
ࢇԥʯ ʼݨࡶ ̧̛֙ए ٕ࣐ଞ ࢵձ एѦଥ࣯ݦ ࡬ॹࠞ ˬܹЧ, ˬܹЧࡶ 
ଯଞ ʃیࢂ ցࡸࡶ ߭ӊʯ ̔Ի Ь ૲ୃଟ ܹ ࢑ࡶ̧ࡁ. ˬܹЧࡵ ࢿ 
߇ࢂ ࢖ࡵ ʨࡶ ߊ߅و ࣯܏ˈ, ଞ ࢂیԻ۰ࢂ ܕߦ ڸ ߅ТԂ ۓࢂ 
࢕ۿ߾ оଞ ɼծ৚ࡶ ࣯܏ݡТЬ. ˬܹЧࢂ ࠊࢽ˕ एѦ щٗ߾ 
ଝࡢ˕ࢽࡶ Ζ̧ए ց৘ ܹ ࢑߹ݡТЬ. ؃ی˕ࢽ Ѱ߇ ˬܹЧࢂ ɼծ৚ࡶ 
੼ଥ ࡪࢷ࢕৔ՎԄ ଝח߾ ֐ԯࡶ ГΚ ܹ ࢑߹ˈ, ଝח߾ оଞ Ζ߷Е 
ʀऎ˕ ࠉ˱߾ ֐ऑଜݤЕ ֻݡࡶ ੼ଥ քࡵ ̳бࡸࡶ ߱߹ݡТЬ. 
ऑݪࡳԻ ʃی ҖվТЬ. ̐ Ѱ߇ ࣯ݦ ɼծ৚ ࢓ए ߉ˈ ۑ߅ɼʵݡТЬ. 
̐չˈ ஒਛ஢ एѦˬܹձ ରԃଥ࣯ݦ ফࢉୖ ˬܹЧ, Ϣח ݪیձ 
֎߅࣯ݤˈ, ܕࣸଞ ঻ˈࠪ ࣏߯ࡶ ߅Ηए ߉ࡳݦ ݦࢷܹ ˬܹЧ, ؃ݣࡉ 
ˬܹЧ, ̐չˈ ࡬׵ऑ ˬܹЧ͉ ̦ࡵ ʃیձ ҖվТЬ. ଝחࡶ یԊଜЕ 
ଝ࢕Ի۰ࢂ ֻݡࡶ ੼ଥ ତۘ ̆ʃࢇ Ѹ࣯߭ݤЕ ָۢ˓ଝ˕ ˬܹЧҚ͉Ѧ 
   
ʃیձ ҖվТЬ.  
ࡪࢷ࢕৔Վ ࠉ˱ݨ߾ ࢏ଝଞ ࢇ୯Ի ଡ͉ଜֲ Ѧࡏࡶ ࣯܏ы ۴ؑЧҚ˕ 
୯ؑЧҚ͉ ࠇݤ ̦ࡵ ʃیձ ҖվТЬ. ࣑ˁݛԜࡋ ׷ࢽ ߯Т, ஦ࢇ 
Ѹࣱ߭ एୱ ࠝڃ, ߇ݥঈɼ Ѹࣱ߭ ߅ղ ߯Т, Мԯ ࢑Е ࢽࡉ ࠝڃ, 
ؑࡌࢺࢇ ࢽֆ քࡵ ࢽ۴ ߯Т, ତۘ ऑݪࡳԻ Ьɼࣱࠪ ࢊ̍ ࠝڃ, քࡵ 
ɼծ৚ࡶ ࣯ݦ ܞΧ ࠝڃ, ࢂएɼ ѹ ੓ऑ ࠝڃ, ࡪМଞ ࣱࠝࢇ, ʃ۽ࢶࢉ 
ए۽ࢇ, ӗٕԜऑ ୊ࡕࢇ, ଥଔ؂ࢇԜݛ ۽ˁࢇ, Ҝऐଞ ࣯߯, ۴ؑ ʋࡵ 
୯ؑ ଛ਺ڂ ࡪऑࢇ, ٕएԞଞ টஜ, ߺӦଞ ୪׷ࢇ, Мԯ࢕ kasala ؃یЧ, 
ٗࡢ̛ ֩ࢇ৲ ܹࢽࢇ, ؿˈݮࡵ ୯ؑ ࣗୃࢇ, ΟϠય ۴ࢠ ܹ୚ࢇ, ߅ଏ 
ܘɼԃ ࢽࡵࢇ, ۑսͲ ؿˁࢇ, Χ࢕Ьࡋ ࡕݥࢇ, ۹ۿଞ җࠒࢇ, Ѧࡏࡶ 
քࢇ ࣱ ऑࡉ, ੉˲߾۰ ˈۢଜЕ শࠒࢇ, ࢊ ࢚ଜЕ ੓̑ࢇ, ॺࢎʃ ࢑Е 
ଜЖࢇ, ̛о࣯ ࡈୃࢇࠪ ୊Զࢇ ֻѿ ऑݪࡳԻ ʃیҖվТЬ. 
ה߸ؿЬѦ ࢵ߾ оଞ ʡࢽࡳԻ ଜՔଜՔձ ۑ߅ɼݤˈ ˃ݦ یԊଜЕ 
ֻٕЧ͉ ʃیҖվТЬ. 
ࢇ ࠹߾ ࢿɼ ׵ঈ ̗߯ଜए ׃ଞ ˈցࡋ ٗҚࢇ οהΟ քݡТЬ. ̐ 
ٗҚࢂ ࢇղࡶ ֻѿ ̛ۚए ׃ଡࡶ ࣤܞଜʯ ۢɽଜֲ, оݦ ࢿ ̦ࡵ 
ʃیࢂ ֆԻ ࢇ ̔ࡶ ց৛ТЬ. ³ऑݪࡳԻ ʃیҖվТЬ´ 
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ABSTRACT 
 
Improved therapeutic efficacy of decorin expressing oncolytic 
adenovirus driven by cancer- and tumor microenvironment-
specific promoter in pancreatic cancer 
 
Yan Li 
 
Graduate Program for Nanomedical Science 
The Graduate School 
 Yonsei University 
 
(Directed by Professor In-Hong Choi) 
 
Pancreatic cancer is a leading cause of cancer-related death. Desmoplastic 
pancreatic tumors exhibit excessive extracellular matrix (ECM) and are thus 
highly resistant to anticancer therapeutics, since the ECM restricts drug 
penetration and dispersion. Here, we designed and generated two hypoxia-
responsive and cancer-specific hybrid promoters, HmTE and HEmT. Transgene 
expression driven by each hybrid promoter was markedly higher under hypoxic 
conditions than normoxic conditions. Moreover, HEmT-driven transgene 
expression was highly cancer-specific and was superior to that of HmTE-driven 
expression. A decorin-expressing oncolytic adenovirus (Ad; oHEmT-DCN) 
 リ 
 
replicating under the control of the HEmT promoter induced more potent and 
highly cancer-specific cell death compared with its cognate control oncolytic 
Ad, which harbored the endogenous Ad E1A promoter. Moreover, oHEmT-
DCN exhibited enhanced antitumor efficacy compared with both the clinically 
approved oncolytic Ad ONYX-015 and its cognate control oncolytic Ad 
lacking DCN. oHEmT-DCN treatment also attenuated the expression of major 
ECM components, such as collagen I/III, elastin, and fibronectin, and induced 
tumor cell apoptosis, leading to extensive viral dispersion within orthotopic 
pancreatic tumors and pancreatic cancer patient-derived tumor spheroids. 
Collectively, these findings demonstrate that oHEmT-DCN exhibits potent 
antitumor efficacy by degrading the ECM and inducing apoptosis in a 
multifunctional process. This process facilitates the dispersion and replication 
of oncolytic Ad, making it an attractive candidate for the treatment of 
aggressive and desmoplastic pancreatic cancer. 
 
 
Key word: Oncolytic adenovirus; Pancreatic cancer; Decorin; Hypoxia; 
     Desmoplasia; Cancer-specific promoter; Extracellular matrix
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I. INTRODUCTION 
 
Pancreatic cancer is the fourth leading cause of cancer-related death in 
Europe and the United States [1]. Only 10-20% of all patients with pancreatic 
cancer are resectable at presentation. The US National Cancer Institute recently 
reported that the overall 5-year relative survival rate for 2002-2008 was 5.8%, 
and nearly 90% of all patients were dead 1 year after diagnosis, with a median 
survival of less than 6 months [2, 3]. One experimental treatment option of 
particular interest for pancreatic cancer is oncolytic virotherapy, which utilizes 
viral vectors to preferentially replicate in tumor cells and induce cancer cell 
death. Among the various viral vectors that have been tested, adenovirus (Ad) 
has been most extensively utilized in gene therapy applications, and sufficient 
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data from randomized clinical trials support its safety in patients [4-6]. 
Although oncolytic Ad-mediated cancer gene therapy is highly promising, 
significant therapeutic efficacy of oncolytic Ad for the treatment of localized 
tumors has not yet been achieved in clinical trials; thus, further improvements 
are needed [7, 8]. 
Hypoperfusion and desmoplasia are two prominent features of 
pancreatic cancer that attenuate the therapeutic efficacy of cancer therapeutics 
[9]. Aberrant extracellular matrix (ECM) functions as a protective layer that 
prevents drug penetration and diffusion into the pancreatic tumors, contributing 
to poor disease management by conventional treatment modalities. 
Furthermore, hypoxia, a condition characterized by oxygen deprivation caused 
by abnormal microcirculation and vascularization in the tumor 
microenvironment, promotes cancer progression and attenuates the therapeutic 
efficacy of oncolytic Ad by suppressing viral replication through 
downregulation of Ad E1A protein expression [10-12]. 
Decorin (DCN), a ubiquitous component of the ECM, is preferentially 
found in association with collagen fibrils. Furthermore, DCN regulates the 
production of other ECM components by blocking the activity of transforming 
growth factor-ȕ (TGF-ȕZKLFKLVDPDMRULQGXFHURIGHVPRSODVLDLQSDQFUHDWLF
tumors [13]. We previously demonstrated that oncolytic Ad-mediated 
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intratumoral expression of DCN can drive degradation of the ECM and inhibit 
ECM production, thereby enhancing viral penetration and dispersion within 
solid tumors and making DCN a promising therapeutic gene for the treatment 
of desmoplastic tumors [14].  
A successful oncolytic Ad-mediated cancer gene therapy requires good 
cancer-specificity, since ectopic replication of Ad at nontarget tissues will 
result in cytotoxicity. In this regard, numerous studies have been conducted 
with the aim of achieving selective replication of Ad in a cancer cell-specific 
manner. A particularly promising approach for endowing cancer-specificity to 
replication-competent Ad is to restrict viral replication to cancer cells by 
replacing the endogenous Ad promoter with a cancer cell-specific promoter. 
Among the cancer-specific promoters, both the E2F and human telomerase 
reverse transcriptase (hTERT) promoters have demonstrated good cancer 
specificity [15, 16]. We previously showed that oncolytic Ad replicating under 
the control of a modified hTERT (mTERT) promoter containing additional c-
Myc and Sp1 binding sites replicates more efficiently and preferentially in 
tumor cells than its cognate control Ad replicating under the wild-type hTERT 
promoter, resulting in more potent Ad E1A-mediated apoptosis and viral 
cytolysis in a cancer-restricted manner [17]. However, the therapeutic effect of 
oncolytic Ad in the hypoxic region of the tumor nest was still insufficient, since 
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hypoxia directly impacts the therapeutic efficacy of oncolytic Ad by 
suppressing viral replication through attenuation of Ad E1A protein expression 
[10-12].  
To overcome this hypoxia-induced downregulation of Ad E1A 
expression in solid tumors and to enhance their cancer-selective promoter 
activity, we designed and generated two different enhancer/promoter hybrids 
that incorporate 6 copies of the hypoxia response element (HRE) upstream of 
either the E2F or modified human telomerase reverse transcription (mTERT) 
promoter. This strategy generated an HRE-mTERT-E2F hybrid promoter 
(HmTE) and an HRE-E2F-mTERT hybrid promoter (HEmT). In this study, we 
demonstrate that DCN-expressing oncolytic Ad replicating under the control of 
the HEmT hybrid promoter (oHEmT-DCN) exerts potent tumoricidal effects by 
efficaciously and preferentially replicating in both hypoxic and normoxic 
regions of highly desmoplastic pancreatic tumors. 
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II. MATERIALS AND METHODS 
 
Cell lines and cell culture 
All cell lines with the exception of normal pancreatic cells (NPC), 
ZKLFK ZDV PDLQWDLQHG LQ SULJURZ , PHGLXP ZHUH FXOWXUHG LQ 'XOEHFFR¶V
PRGLILHG (DJOH¶V PHGLXP '0(0 *,%&2 %5/ *UDQG ,VODQG 1<
supplemented with 10% fetal bovine serum (GIBCO BRL) and penicillin-
streptomycin (100 IU/mL, GIBCO BRL). The HEK293 (human embryonic 
kidney cell line expressing the Ad E1 region), A549 (human lung cancer cell 
line), MIA PaCa-2 and PANC-1 (pancreatic cancer cell lines), and human 
dermal fibroblast (HDF; normal fibroblast cell line) cell lines were purchased 
from the American Type Culture Collection (ATCC, Manassas, VA). The NPC 
cell line was purchased from Applied Biological Materials (ABM, Richmond, 
Canada). All cell lines were maintained at 37°C in a humidified atmosphere at 
5% CO2. 
 
Animal studies 
Six to eight-week-old male athymic nude mice were purchased from 
Charles River Korea (Sungnam, Korea) and maintained in a laminar air flow 
cabinet under specific pathogen-free environment. All facilities were approved 
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by AAALAC (Association for Assessment and Accreditation of Laboratory 
Animal Care). All of the animal experiments were conducted according to the 
institutional guidelines established for the Hanyang University Institutional 
Animal Care and Use Committee. 
 
Construction of the Ad vectors 
To generate the two different cancer-specific hybrid promoters, 
HRE/mTERT/E2F (HmTE) and HRE/E2F/mTERT (HEmT), the HRE enhancer, 
E2F, and the mTERT promoter were inserted into pDE1sp1B, thereby 
generating pDE1sp1B-HmTE and pDE1sp1B-HEmT [10, 17, 18]. To construct 
E1 shuttle vectors expressing green fluorescent protein (GFP) under the control 
of the modified cancer-specific promoters (HmTE and HEmT), the sequence 
encoding GFP was subcloned from pEGFP-N1 using Xho I/Afl II. This GFP 
gene was then ligated into pDE1sp1B/HmTE and pDE1sp1B/HEmT cut with 
the same restriction enzymes, thereby generating the pDE1sp1B/HmTE-GFP 
and pDE1sp1B/HEmT-GFP Ad E1 shuttle vectors. The Ad E1 shuttle vectors 
were linearized by Xmn I digestion, whereas the Ad vector dE1-k35 was 
linearized with BstB I digestion. The linearized Ad shuttle vectors were 
cotransformed into Escherichia coli BJ5183 cells with BstB I-digested dE1-k35 
to allow for homologous recombination. The resultant homologously 
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recombined Ad plasmid was digested with Pac I and transfected into HEK293 
cells to generate the replication-incompetent Ads, dHmTE-GFP and dHEmT-
GFP. GFP-expressing Ad under the control of the cytomegalovirus (CMV) 
promoter (dCMV-GFP) was used as a control [19, 20]. 
To create an oncolytic Ad replicating under the control of the HEmT 
promoter, a template Ad plasmid consisting of the E1B 19kDa region-deleted 
E1 shuttle vector (pDE1sp1B/Rd19) harboring the retinoblastoma binding sites 
of mutant E1A was used [21, 22]. Initially, the HEmT promoter was inserted 
into pDE1sp1B/Rd19, thereby generating the pDE1sp1B/HEmT-Rd19 Ad E1 
shuttle vector. To create a DCN-expressing replicating Ad vector, the sequence 
encoding DCN was subcloned from pCA14/DCN using Bgl II into 
pDE1sp1B/HEmT-Rd19, thereby generating the pDE1sp1B/HEmT-Rd19/DCN 
Ad E1 shuttle vector. These Ad E1 shuttle vectors (pDE1sp1B/Rd19, 
pDE1sp1B/HEmT-Rd19, and pDE1sp1B/HEmT-Rd19/DCN) were linearized 
with Xmn I and then cotransformed into Escherichia coli BJ5183 cells with 
linearized dE1-k35 to allow for homologous recombination, thus generating the 
oRd19 (Rd19-k35), oHEmT (HEmT-Rd19-k35), and oHEmT-DCN (HEmT-
Rd19-k35/DCN) oncolytic Ad plasmids, respectively. The resultant 
homologously recombined Ad plasmids were digested with Pac I and 
transfected into HEK293 cells to generate the replication-competent Ads 
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oRd19, oHEmT, and oHEmT-DCN.  
Replication-incompetent Ad and replication-competent oncolytic Ad 
were propagated in HEK293 cells and A549 cells, respectively. All viruses were 
obtained as previously described [21]. The numbers of viral particles (VP) were 
calculated from optical density measurements at 260 nm (OD260), where 1 
absorbency unit (OD260 = 1) indicated a concentration of 1.1 × 1012 VP/mL. 
3XULILHGYLUXVHVZHUHVWRUHGDWí&XQWLOXVH 
 
Transduction efficiency analysis 
To assess the transcriptional activity of the HmTE and HEmT promoters 
under normoxic and hypoxic conditions, fluorescence microscopy and 
fluorescence-activated cell sorting (FACS) analysis were carried out. Pancreatic 
cancer cells (MIA PaCa-2 and PANC-1) were transduced with GFP-expressing 
replication-incompetent Ad under the control of the HmTE or the HEmT 
promoter at an MOI of 50. At 48 hr post-transduction, cells were imaged using 
D ÀXRUHVFHQFHPLFURVFRSH &DUO =HLVV ,QF 7KRUQZRRG1< DQG WKH*)3
H[SUHVVLRQ OHYHOV ZHUH TXDQWL¿HG XVLQJ D )$&6&DOLEXU DQDO\]HU %HFWRQ-
Dickinson, San Jose, CA). All FACS data were analyzed using CellQuest 
software (Becton-Dickinson). Approximately 10,000 events were counted for 
each sample. 
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To assess the cancer specificity of the CMV and HEmT promoters, 
fluorescence microscopy and FACS analysis were carried out. Cells were 
transduced with GFP-expressing Ad under the control of the CMV promoter or 
the HEmT promoter at MOIs of 5, 20, and 50. At 48 hr post-transduction, cells 
ZHUHLPDJHGE\ÀXRUHVFHQFHPLFURVFRS\DQGWKH*)3H[SUHVVLRQ OHYHOZDV
TXDQWL¿HG XVLQJ D )$&6&DOLEXU DQDO\]HU DQG &HOO4uest software. 
Approximately 10,000 events were counted for each sample. 
 
MTT assay 
To evaluate the extent to which HEmT-regulated oncolytic Ad (oHEmT) 
selectively kills cancer cells, pancreatic cancer cells (MIA PaCa-2 and PANC-
1) and normal cells (NPCs and HDFs) seeded in 24-well plates were infected 
with oHEmT (or oRd19 as the cognate control) at an MOI of 2 under either 
normoxic or hypoxic conditions. At 60 hr post-LQIHFWLRQ  ȝ/ RI -(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT; Sigma, St. 
Louis, MO) in phosphate-buffered saline (PBS; 2 mg/mL) was added to each 
well. After 4 hr of incubation at 37°C, the supernatant was discarded from each 
well, and the precipitate was dissolved in dimethylsulfoxide. The absorbance 
of each well at 540 nm was then read on a microplate reader. All assays were 
performed in triplicate. The number of living cells in the untreated cell group 
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was analyzed in an identical manner as a negative control. 
To evaluate the extent to which DCN-expressing oncolytic Ad (oHEmT-
DCN) and the control oncolytic Ad (oHEmT) specifically kill cancer cells, and 
to determine whether this effect is dose-dependent, pancreatic cancer cells 
(MIA PaCa-2 and PANC-1) and normal cells (NPCs and HDFs) were grown in 
24-well plates to 50-60% confluency. Next, cells were infected with oHEmT or 
oHEmT-DCN at an MOI of 1, 2, or 5. At 72 hr post-infection, the MTT assay 
was performed as described above. 
In addition, the kinetics of pancreatic cancer cell killing by oncolytic 
Ads (oHEmT and oHEmT-DCN) was analyzed by the MTT assay. Specifically, 
upon reaching approximately 50-60% confluence, cells in 24-well plates were 
infected (MOI = 2) with oHEmT or oHEmT-DCN. The MTT assay was then 
performed at 24, 48, and 72 hr post-infection as described above. 
 
Virus production assay 
To assess the viral production of oncolytic Ads, pancreatic cancer cells 
and normal cells were seeded in 24-well plates at approximately 60% 
confluency and then infected with oRd19 or oHEmT at an MOI of 0.5 
(pancreatic cancer cells) or 10 (normal cells). After 48 hr of incubation at 37°C 
under either normoxic or hypoxic conditions, supernatants and cell pellets were 
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collected and freeze-thawed three times to release internal virus. Real-time 
quantitative PCR (Q-PCR; TaqMan PCR detection; Applied Biosystems, Foster 
City, CA) was used to assess the number of viral genomes in each sample. 
Samples were analyzed in triplicate, and data were processed using the SDS 
19.1 software package (Applied Biosystems). 
 
Enzyme-linked immunosorbent assay (ELISA) measuring the levels of 
secreted decorin and TGF-ȕH[SUHVVLRQ 
Pancreatic cancer cells (MIA PaCa-2 and PANC-1) and normal cells 
(NPCs and HDFs) were seeded in 24-well plates at approximately 60% 
confluency and then infected with oHEmT-DCN at an MOI of 0.5 or 2. At 2 
days post-infection, supernatants were collected by centrifugation at 15,000 × 
g for 10 min at 4°C, and the level of secreted DCN was assessed using an ELISA 
kit (Abcam, Ltd., Cambridge, UK). 
To evaluate TGF-ȕ H[SUHVVLRQ LQ WXPRU WLVVXH WXPRU WLVVXHV ZHUH
collected from mice treated with PBS or oncolytic Ads (ONYX-015, oHEmT, 
or oHEmT-DCN) at 30 days after the administration of the first viral treatment. 
Tumor tissues were homogenized in ice-cold RIPA buffer (Elipis Biotech, 
Taejeon, South Korea) containing a proteinase inhibitor cocktail (Sigma). 
Homogenates were then centrifuged in a high-speed microcentrifuge for 10 min, 
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after which total protein contents were determined using a BCA protein assay 
kit (Pierce, Rockford, IL). The level of TGF-ȕ ZDV PHDVXUHG E\ D
conventional ELISA kit (R&D Systems, Minneapolis, MN).  
 
Assessment of antitumor effects in an orthotopic model of human pancreatic 
cancer 
MIA PaCa-2 cells (5 × 106), which stably express firefly luciferase, were 
injected into the pancreas of athymic nude mice. At 2 weeks post-implantation 
(day 0), mice were divided into four separate groups in order to receive 
intraperitoneal treatment of PBS, ONYX-015, oHEmT, or oHEmT-DCN (n=6 
per group). Optical imaging was carried out every five days following the first 
treatment with an IVIS SPECTRUM instrument (Xenogen Corp., Alameda, 
CA). Image signals were quantitatively analyzed with IGOR-PRO Living 
Image software (Xenogen). At 30 days after the first treatment, tumors were 
collected, imaged, weighed, and sectioned. 
 
Western blot analysis 
To evaluate the levels of DCN and Ad E1A protein expression in tumor 
cell lysates from MIA PaCa-2 pancreatic orthotopic models, tumors were 
collected from Ad-treated mice at 30 days after the first viral treatment. Tumors 
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were homogenized in ice-cold RIPA buffer containing a proteinase inhibitor 
cocktail. The resultant homogenates were then centrifuged in a high-speed 
microcentrifuge for 10 min. Protein concentrations were determined by the 
%&$ SURWHLQ DVVD\ DQG HTXDO SURWHLQ DPRXQWV  ȝJ SHU VDPSOH ZHUH
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The 
proteins were electrotransferred to polyvinylidene fluoride membranes and 
incubated with goat anti-DCN antibody (Ab; R&D Systems), rabbit anti-Ad 
E1A Ab (Santa Cruz Biotechnology, Santa Cruz, CA), or rabbit anti-ȕ-actin Ab 
(Cell Signaling Technology, Beverly, MA). Next, the membranes were 
incubated with secondary horseradish peroxidase-conjugated goat anti-rabbit 
IgG or mouse anti-goat IgG Ab (Cell Signaling). Immunoreactive bands were 
visualized via enhanced chemiluminescence (Amersham Pharmacia Biotech, 
Uppsala, Sweden). The expression levels of Ad E1A and DCN were semi-
quantitatively analyzed using ImageJ software (National Institutes of Health, 
Bethesda, MD). 
 
Histology and immunohistochemistry 
Representative sections were stained with hematoxylin and eosin (H & 
( SLFURVLULXV UHG RU0DVVRQ¶V WULFKURPH DQG WKHQ H[DPLQHG XVLQJ D OLJKW
microscope (Carl Zeiss Inc.). Pancreatic tumor tissue sections and pancreatic 
 ラヮ 
 
tumor spheroid sections were incubated at 4°C overnight with mouse anti-
collagen type I (Abcam), mouse anti-collagen type III (Sigma), mouse anti-
elastin (Sigma), mouse anti-fibronectin (Santa Cruz Biotechnology), rabbit 
anti-Ad E1A, or mouse anti-proliferating cell nuclear antigen (PCNA; DAKO, 
Glostrup, Denmark) primary Ab and then treated with an ABC-peroxidase kit 
(ChemMate DAKO Envision kit; DAKO, Carpinteria, CA). All slides were 
FRXQWHUVWDLQHG ZLWK 0H\HU¶V KHPDWR[\OLQ (Sigma), with the exception of 
picrosirius red-VWDLQHGDQG0DVVRQ¶V trichrome (Sigma)-stained slides, which 
ZHUH FRXQWHUVWDLQHGZLWK+DUULV¶ KHPDWR[\OLQ (Sigma). Collagen expression 
ZDVGHWHFWHGE\0DVVRQ¶V WULFKURPHRUSLFURVLULXV UHGVWDLQLQJZKHUHDV WKH
expression levels of Ad E1A, PCNA, type I and III collagen, elastin, and 
fibronectin in tumor tissues were detected by specific Ab staining. Expression 
levels were semi-quantitatively analyzed using MetaMorph® image analysis 
software (Universal Image Corp., Buckinghamshire, UK). Each result is 
expressed as the mean optical density of five different digital images. 
 
Immunofluorescence staining 
For immunofluorescence staining of Ad E1A and hypoxia-inducible 
IDFWRUĮ+,)-Į, tumor sections were treated with rabbit anti-Ad E1A Ab or 
mouse anti-human HIF-ĮAb (Abcam) and incubated overnight at 4°C. Next, 
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the tumor sections were treated with Alexa Fluor 568 (red)-conjugated goat 
anti-rabbit IgG (Invitrogen, Carlsbad, CA) or Alexa Fluor 488 (green)-
conjugated goat anti-mouse IgG (Invitrogen) Ab at room temperature for 1 hr. 
For counterstaining, the samples were incubated with 4,6-diamidino-2-
phenylindole (Sigma). The slides were mounted with Vectashield mounting 
medium (Vector Laboratories, Burlingame, CA) and imaged under a confocal 
laser-scanning microscope (LSM510, Carl Zeiss MicroImaging, Thornwood, 
NY). 
 
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling Assay 
Formalin-fixed and paraffin-embedded tissue sections (5-mm) were 
deparaffinized and rehydrated according to standard protocols [23]. Apoptosis 
was detected terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay (DeadEndTM Fluorometric TUNEL System; Promega, Madison, 
WI). Briefly, tissue sections were permeabilized with proteinase K (20 mg/mL) 
for 10 min at room temperature. Sections were then incubated with terminal 
deoxynucleotidyl transferase (TdT) and fluorescein-12-dUTP in TdT buffer at 
room temperature for 60 min and washed with TdT buffer. Finally, nuclei were 
counterstained with methyl green (Sigma). The samples were analyzed by light 
microscopy. The amount of apoptotic cells was semi-quantitatively analyzed 
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using MetaMorph® image analysis software. Each result is expressed as the 
mean optical density of five different digital images. 
 
Preparation of pancreatic cancer patient-derived tumor spheroids 
Primary pancreatic cancer tumors were obtained from patients with 
active-stage pancreatic cancer (n=3). Pancreatic cancer patient-derived tumor 
spheroids were prepared as previously described [14]. Plates containing the 
tumor spheroids were treated with oncolytic Ad (1 × 1010 VP of ONYX-015, 
oHEmT, or oHEmT-DCN) on days 1 and 4 and incubated at 37°C for 6 days. 
The treated tumor spheroids were then fixed with 10% formalin, embedded in 
paraffin, and cut into 5-ȝP-thick sections. 
 
Statistical analysis 
All data are expressed as mean ± standard deviation (SD). Statistical 
significance was determined by the two-WDLOHG 6WXGHQW¶V t-test (SPSS 13.0 
software; SPSS, Chicago, IL) and one-way ANOVA. Differences were 
considered statistically significant at ƒP < 0.05, ƒƒP < 0.01, and ƒƒƒP < 0.001. 
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III. RESULTS 
 
Potent and tumor-selective activity of the HEmT promoter 
The E2F and TERT promoters are established cancer-specific 
promoters that have been frequently utilized to endow cancer specificity to Ads 
[15, 17]. However, cancer-specific promoters alone cannot prevent the 
attenuation of Ad replication in the context of the hypoxic tumor 
microenvironment. To overcome hypoxia-induced downregulation of Ad E1A 
expression and enhance the promoter activity in cancer cells, we constructed 
two variants of a cancer-specific hybrid promoter, HRE/E2F/mTERT (HEmT) 
and HRE/mTERT/E2F (HmTE), by inserting 6 copies of the HRE upstream of 
either the E2F or mTERT promoter. 
To compare the promoter activities of the HRE-harboring hybrid 
promoters, two different replication-incompetent Ads expressing GFP under 
the control of the HEmT or HmTE promoter were generated (dHmTE-GFP and 
dHEmT-GFP, respectively; Figure 1A). Pancreatic cancer cells (MIA PaCa-2 
and PANC-1) were then transduced with either dHmTE-GFP or dHEmT-GFP, 
which were under the control of the hybrid promoters, for 48 hr. As shown in 
Figure 2A and B, dHEmT-GFP induced significantly higher GFP expression 
than dHmTE-GFP under normoxic conditions in both MIA PaCa-2 and PANC-
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1 cells (**P < 0.01, ***P < 0.001, respectively), demonstrating the superior 
transcriptional activity of the HEmT promoter. More importantly, HEmT 
promoter activity was significantly enhanced under hypoxic conditions 
compared with normoxic conditions (***P < 0.001), demonstrating that 
insertion of the HRE enhancer upstream of a cancer-specific hybrid promoter 
can enhance Ad-mediated transgene expression under hypoxic conditions. 
Based on these results, the HEmT promoter was selected as a more potent 
promoter than the HmTE promoter and was utilized in subsequent experiments. 
To assess the cancer selectivity of the HEmT promoter, pancreatic 
cancer cells (MIA PaCa-2 and PANC-1) or normal cells (NPCs and HDFs) 
were transduced with replication-incompetent GFP-expressing Ad under the 
control of either the CMV or HEmT promoter (dCMV-GFP and dHEmT-GFP, 
respectively). As shown in Figure 3A and B, both dCMV-GFP and dHEmT-
GFP conferred a dose-dependent increase in relative GFP expression in 
pancreatic cancer cells. In contrast, negligible GFP expression was observed in 
dHEmT-GFP-transduced normal cells, even at a high multiplicity of infection 
(MOI) (50). In contrast, dCMV-GFP induced dose-dependent GFP expression 
in normal cells. Of particular note, dHEmT-GFP induced 31.9-fold and 72.0-
fold lower GFP expression than dCMV-GFP at an MOI of 50 in NPC and HDF 
cells, respectively (***P < 0.001). These results demonstrate that the HEmT 
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promoter is highly cancer cell-selective, exhibits good transcriptional activity 
in tumor cells, and drives only minimal transcriptional activity in normal cells. 
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Figure 1. Construction of the Ads used in this study. (A) Replication-
incompetent Ads expressing GFP under the control of the CMV, HmTE, or 
HEmT promoter. (B) Oncolytic Ads oRd19 contains a mutated E1A sequence 
and lacks the E1B 19kDa gene; E1A expression is controlled by the endogenous 
promoter. oHEmT contains a hypoxia-responsive enhancer and cancer-specific 
promoter (HEmT), which replaces the endogenous E1A promoter of oRd19. 
oHEmT-DCN contains the sequence encoding DCN in the E1 region of 
oHEmT.  
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Figure 2. Levels of GFP expression driven by the HmTE or HEmT promoter 
in human pancreatic cancer cell lines (MIA PaCa-2 and PANC-1). Cells were 
transduced with Ads expressing GFP under the control of the HmTE or HEmT 
promoter (dHmTE or dHEmT) at an MOI of 50 under normoxic or hypoxic 
conditions. Fluorescence images (A) and quantitative FACS analysis (B) of 
GFP expression. Expression was analyzed after 48 hr incubation at 37°C. Data 
shown are representative of three independent experiments, each performed in 
triplicate. Bars represent mean ± SD. **P < 0.01 and ***P < 0.001. 
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Figure 3. GFP expression driven by the cancer cell-specific promoter. Levels 
of GFP expression driven by the CMV or HEmT promoter (dCMV or dHEmT) 
in human pancreatic cancer (MIA PaCa-2 and PANC-1) and normal cell lines 
(NPC and HDF). Cells were transduced with Ads expressing GFP under the 
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control of the CMV or HEmT promoter at an MOI of 5, 20, or 50. Fluorescence 
images (A) and quantitative FACS analysis (B) of GFP expression. Expression 
was analyzed after 48 hr incubation at 37°C. Data shown are representative of 
three independent experiments, each performed in triplicate. Bars represent 
mean ± SD. ***P < 0.001. 
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Cancer cell-specific killing effect of HEmT promoter-regulated oncolytic Ad 
We previously reported that oncolytic Ad containing mutated E1A 
retinoblastoma binding sites and harboring a deletion of the E1B 19kDa region 
(oRd19) exhibits potent cancer cell killing efficacy and good cancer specificity 
[21, 24]. In an effort to improve the cancer cell-specific viral replication and 
killing effects, we replaced the endogenous oRd19 promoter of the Ad E1A 
gene with the HEmT promoter, thus generating an oHEmT oncolytic Ad 
(Figure 1B).  
To assess whether oHEmT oncolytic Ad could replicate and induce cell 
killing in a cancer-selective manner, cancer and normal cells were infected with 
oRd19 or oHEmT for 60 hr at an MOI of 2. As shown in Figure 4, oHEmT 
killed pancreatic cancer cells (MIA PaCa-2 and PANC-1) more efficiently than 
oRd19 under both normoxic and hypoxic conditions (***P < 0.001), whereas 
no cell killing was observed in normal cells (NPCs and HDFs). These findings 
indicate that oHEmT exhibits more potent cancer cell-specific killing efficacy 
than oRd19. Of particular note, oHEmT was not cytotoxic to normal cells under 
hypoxic conditions, indicating that incorporation of the HRE enhancer into the 
oHEmT promoter did not affect the cancer specificity of oncolytic Ad under 
hypoxic conditions. Specifically, oHEmT exhibited significantly higher cancer 
cell killing under hypoxic conditions than under normoxic conditions (18.1% 
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and 16.0% higher than in normoxic conditions in MIA PaCa-2 and PANC-1 
cells, respectively; **P < 0.01, ***P < 0.001). In contrast, no significant 
difference was detected in pancreatic cancer cells treated with oRd19 under 
hypoxic vs. normoxic conditions, indicating that oHEmT can overcome 
hypoxia-mediated attenuation of Ad E1A protein expression. Altogether, these 
results suggest that the HEmT promoter can enable replication-competent Ad 
to overcome hypoxia-mediated attenuation of viral replication and 
preferentially induce potent cancer cell killing.  
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Figure 4. &DQFHUFHOONLOOLQJHI¿FDF\RIR5GDQGR+(P7XQGHUQRUPR[LF
and hypoxic conditions. Pancreatic cancer and normal cells were treated with 
oRd19 or oHEmT at an MOI of 2. Cell viability was assessed by the MTT assay. 
The viability of untreated cells was set to 100%. Data shown are representative 
of three independent experiments, each performed in triplicate. Bars represent 
mean ± SD. **P<0.01 and ***P < 0.001. 
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Cancer cell-restricted replication of Ads controlled by the HEmT promoter 
To assess whether oHEmT-induced cytotoxicity was dependent on viral 
replication, pancreatic cancer cells were infected for 48 hr at an MOI of 0.5 
with oHEmT or its cognate control, oRd19 (Figure 5). In MIA PaCa-2 cells, 
oHEmT exhibited 2.1-fold and 4.6-fold higher viral production than oRd19 
under normoxic and hypoxic conditions, respectively (**P < 0.01, ***P < 
0.001). Similar results were observed in PANC-1 cells. These results indicate 
that the activity of the HEmT promoter is superior in both normoxic and 
hypoxic conditions to that of the endogenous Ad E1A promoter. Furthermore, 
viral replication of oHEmT was significantly lower than, or similar to, that of 
oRd19 in NPCs and HDFs at a high MOI (10), indicating that HEmT promoter-
driven viral replication is highly cancer-specific. Taken together, these results 
demonstrate that the HEmT promoter can induce cancer-specific and proficient 
viral replication of oncolytic Ad under both normoxic and hypoxic conditions. 
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Figure 5. Viral production of oRd19 and oHEmT. Cells were treated with 
oRd19 or oHEmT at an MOI of 0.5 (pancreatic cancer cells) or 10 (normal 
cells). Viral production was assessed by Q-PCR at 48 hr after infection. Data 
shown are representative of three independent experiments, each performed in 
triplicate. Bars represent mean ± SD. *P<0.05, **P<0.01, and ***P < 0.001. 
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Cancer cell-specific expression of DCN by oHEmT-DCN 
Desmoplasia, a prominent pathological attribute of pancreatic cancer, is 
marked by a dramatic increase in the proliferation of fibroblasts and increased 
deposition of ECM components [25]. Aberrant deposition of ECM components 
affects the overall elasticity and interstitial fluid pressure of the tumor, which 
can contribute to chemoresistance and poor viral distribution [14, 25]. To 
maximize the therapeutic efficacy of oncolytic Ad for the treatment of 
pancreatic tumors, we generated an HEmT promoter-driven oncolytic Ad 
expressing DCN (oHEmT-DCN). Our rationale for generating this Ad was that 
DCN can degrade aberrant ECM components such as collagen, elastin, and 
fibronectin (Figure 1B).  
To assess whether oHEmT-DCN could induce cancer cell-specific 
expression of DCN, pancreatic cancer and normal cells were infected with 
oHEmT-DCN at an MOI of 0.5 or 2, and culture supernatants were examined 
for DCN secretion by ELISA. As shown in Figure 6, a dose-dependent increase 
in DCN expression was observed in pancreatic cancer cells infected with 
oHEmT-DCN (***P < 0.001). In marked contrast, only negligible DCN 
expression was detected in normal cells. Taken together, these results indicate 
that oHEmT-DCN can efficiently express DCN in a cancer cell-restricted 
manner, presumably due to the HEmT promoter-mediated cancer-specific 
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replication of oncolytic Ad.  
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Figure 6. DCN expression in pancreatic cancer and normal cells infected with 
oHEmT-DCN. Cells were treated with oHEmT-DCN at an MOI of 0.5 or 2. 
DCN expression was assessed at 48 hr after infection by DCN ELISA. Data 
shown are representative of three independent experiments, each performed in 
triplicate. Bars represent mean ± SD. ***P<0.001. 
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Enhanced cancer cell-specific killing of DCN-expressing oncolytic Ad 
We have previously reported that DCN-expressing Ad shows 
increased viral dissemination and greater cytotoxicity than control Ad by 
inducing apoptosis [14]. To determine whether oHEmT-DCN can more 
efficiently induce killing of pancreatic cancer cells than oHEmT, an MTT assay 
was performed to assess cell viability at various time points (Figure 7) and after 
infection with different MOIs (Figure 8). Both oHEmT and oHEmT-DCN 
elicited a time-dependent increase in pancreatic cancer cell killing efficacy, 
indicating that both oncolytic Ads replicate efficiently and induce cancer cell 
death. Importantly, oHEmT-DCN was significantly more cytotoxic to cancer 
cells than oHEmT at all time points (*P < 0.05, **P < 0.01, ***P < 0.001). 
Furthermore, the magnitude of difference in cancer cell killing efficacy was 
greater at later time points, suggesting that replication of oHEmT-DCN and 
subsequent amplification of DCN expression contributed to the potent 
cytopathic effect. 
As shown in Figure 8, both oHEmT and oHEmT-DCN exhibited 
dose-dependent cytotoxicity to pancreatic cancer cells. Importantly, oHEmT-
DCN was significantly more cytotoxic to cancer cells than oHEmT at all doses 
in MIA PaCa-2 and PANC-1 cells, further implying that oncolytic Ad-mediated 
expression of DCN enhances the potency of oncolytic Ad (***P < 0.001). 
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Furthermore, both oncolytic Ads induced only negligible cell death in normal 
cells, indicating that DCN expression is not detrimental to normal cells, and 
that DCN-mediated cell killing is cancer-selective. This result is consistent with 
a previous report in which DCN-mediated induction of apoptosis was shown to 
be cancer-specific [14]. Altogether, these results demonstrate that DCN 
expression mediated by oHEmT-DCN enhances the dose-dependent and time-
dependent cytotoxicity of oncolytic Ad, which occurs specifically in cancer 
cells. 
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Figure 7. &DQFHUFHOONLOOLQJHI¿FDF\RIR+(P7DQGR+(P7-DCN at various 
time points. Pancreatic cancer and normal cells were treated with oHEmT or 
oHEmT-DCN. The MTT assay was carried out at various time points (24-72 
hr). The viability of untreated cells was set to 100%. Data shown are 
representative of three independent experiments, each performed in triplicate. 
Bars represent mean ± SD. *P<0.05, **P<0.01, and ***P < 0.001. 
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Figure 8. &DQFHU FHOO NLOOLQJ HI¿FDF\ RI R+(P7 DQG R+(P7-DCN after 
infection with different MOIs. Pancreatic cancer and normal cells were treated 
with oHEmT or oHEmT-DCN. The MTT assay was carried out after treatment 
with various MOIs (1-5). The viability of untreated cells was set to 100%. Data 
shown are representative of three independent experiments, each performed in 
triplicate. Bars represent mean ± SD. ***P < 0.001. 
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Therapeutic efficacy of oHEmT and oHEmT-DCN in orthotopic pancreatic 
cancer 
Orthotopic tumor models are emerging as a prominent model of cancer 
progression; moreover, the microenvironment of orthotopic tumors closely 
emulates that of clinical tumors [26, 27]. To evaluate the therapeutic potential 
of oHEmT-DCN against pancreatic cancer, we assessed the extent to which 
oncolytic Ads (oHEmT or oHEmT-DCN) could inhibit tumor growth in an 
orthotopic pancreatic cancer model. As a control, we used ONYX-015, a 
clinically approved oncolytic Ad. To monitor and visualize the growth of the 
orthotopic tumors in real time, orthotopic pancreatic tumors were established 
by injecting firefly luciferase-expressing MIA PaCa-2 pancreatic cancer cells 
into the pancreas of Balb/c nude mice. Tumor growth was then monitored by 
bioluminescence optical imaging. 
As shown in Figure 9 and 10, the orthotopic pancreatic tumors 
continued to grow for up to 30 days after the initial treatment in PBS-treated, 
ONYX-015-treated, or oHEmT-treated mice. In contrast, oHEmT-DCN 
treatment resulted in a markedly lower tumor growth rate (***P < 0.001 versus 
PBS; **P < 0.01 versus ONYX-015, oHEmT). At 30 days after the initial 
treatment, the increase in total flux of PBS-treated, ONYX-015-treated, 
oHEmT-treated, and oHEmT-DCN-treated mice averaged 22.2, 24.9, 14.7, and 
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1.4-fold higher than the initial measurement, respectively. Surprisingly, 
ONYX-015 (which is clinically approved) did not suppress tumor growth, 
suggesting that the highly aggressive nature of orthotopic pancreatic tumors 
renders them refractory to treatment with ONYX-015. In marked contrast, both 
oHEmT and oHEmT-DCN suppressed tumor growth more effectively than 
ONYX-015, implying that HEmT promoter-driven oncolytic Ads are highly 
effective for the treatment of pancreatic tumors. Importantly, oHEmT-DCN 
inhibited tumor growth to a significantly greater extent than oHEmT, 
suggesting that oncolytic Ad-mediated DCN expression enhances the antitumor 
efficacy of oncolytic Ad (*P < 0.05, ***P < 0.001). Similarly, tumor weight 
measurements indicated that oHEmT-DCN was a more potent inhibitor of 
tumor growth than ONYX-015 or oHEmT, further supporting our conclusion 
that oHEmT-DCN is well-suited for the treatment of aggressive pancreatic 
tumors (Figure 10; ***P < 0.001 versus ONYX-015 and *P < 0.05 versus 
oHEmT). 
To further investigate the mechanisms behind the antitumor effects of 
the different oncolytic Ads, Western blotting was performed to analyze the 
levels of Ad E1A and DCN expression in the tumors. As shown in Figure 11, 
oHEmT and oHEmT-DCN induced markedly higher expression of Ad E1A in 
tumor tissue than ONYX-015, implying that the HEmT promoter induces high 
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levels of viral replication in pancreatic tumors. Importantly, oHEmT-DCN 
induced 2.1-fold and 4.1-fold higher expression of Ad E1A and DCN, 
respectively, compared with oHEmT. This finding suggests that the potent 
antitumor efficacy of oHEmT-DCN was mediated by active viral replication 
and DCN expression in tumor tissue.  
The TGF-ȕ signaling pathway plays a critical role in the disease 
progression of cancer. This pathway regulates cell growth, differentiation, 
migration, and also induces the epithelial-to-mesenchymal transition (EMT) 
[28]. DCN has been reported to suppress the biological activity of TGF-ȕ by 
preventing TGF-ȕ binding to its receptor [14, 29]. Therefore, we performed 
ELISA to assess whether DCN expression mediated by oncolytic Ads affects 
the intratumoral expression level of TGF-ȕ As shown in Figure 11, the 
intratumoral expression level of TGF-ȕwas significantly suppressed (by 32.6% 
and 26.8%) following treatment with oHEmT-DCN compared with the PBS and 
oHEmT treatments, respectively (**P < 0.01, ***P < 0.001). In contrast, no 
reduction of TGF-ȕ expression was observed in ONYX-015-treated tumor 
tissue. Together, these results demonstrate that DCN expression is positively 
correlated with the suppression of TGF-ȕexpression, and the potent antitumor 
efficacy of oHEmT-DCN was mediated by efficient viral replication, DCN 
expression, and subsequent downregulation of TGF-ȕ 
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Figure 9. Potent tumor growth inhibition by DCN-expressing oncolytic Ad in 
a pancreatic orthotopic tumor xenograft model. Nude mice with MIA PaCa-2 
orthotopic pancreatic tumors were intraperitoneally injected with PBS, ONYX-
015, oHEmT, or oHEmT-DCN at two-day intervals. Firefly luciferase 
expression was monitored every 5 days after treatments using an IVIS imaging 
system.  
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Figure 10. Quantification of bioluminescence signals and tumor weight. 
Bioluminescence signals were calculated in total flux of photons/second (p/s) 
after background subtraction from the region of interest. Tumors were 
harvested at 30 days following the first treatment and measured. Data are 
presented as mean ± SD. *P<0.05, **P<0.01, and ***P < 0.001. 
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Figure 11. Protein expression in tumor tissue. Tumor tissues were lysed to 
generate total protein extracts. Western blotting and TGF-ȕ (/,6$ were 
performed using the resultant tumor lysates. Data are presented as mean ± SD. 
**P<0.01 and ***P < 0.001. 
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Histologic, TUNEL, and immunohistochemical characterization 
The antitumor efficacy of the intraperitoneally administered oncolytic 
Ads was further investigated by histological and immunohistochemical 
analyses. H & E staining revealed a marked reduction in the number of viable 
tumor cells and more extensive necrotic regions in oHEmT-treated and oHEmT-
DCN-treated tumors compared with PBS-treated and ONYX-015-treated 
tumors (Figure 12). Importantly, most of the oHEmT-DCN-treated tumor tissue 
was necrotic, whereas necrotic lesions were detected only in the central region 
of the oHEmT-treated tumor tissue, indicating that oHEmT-DCN can disperse 
through tumor tissue more effectively than oHEmT. Moreover, no necrosis was 
observed in normal tissues adjacent to the oHEmT-DCN-treated tumor tissues, 
suggesting that oHEmT-DCN preferentially induces necrosis in tumors. 
 Ad E1A staining revealed that the oHEmT-DCN-treated tumors 
exhibited markedly higher accumulation of Ad, through a greater area of the 
tumor, than ONYX-015-treated or oHEmT-treated tumors, indicating that 
expression of DCN facilitates viral replication and spreading within solid 
tumors. Consistent with the H & E staining results, no Ad E1A staining was 
observed in the surrounding normal tissues. This finding further confirms that 
the therapeutic effect of oHEmT-DCN is highly cancer-specific, and that tumor 
cell necrosis is induced by efficient viral replication-mediated cytolysis. 
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Tumor cell proliferation was markedly attenuated in oHEmT-DCN-
treated tumors, as assessed by PCNA staining, Furthermore, a markedly higher 
percentage of tumor cells was undergoing apoptosis in oHEmT-DCN-treated 
tumors compared with PBS-treated, ONYX-015-treated, or oHEmT-treated 
tumors, as assessed by the TUNEL assay. Of particular interest, the induction 
level of apoptosis was positively correlated with viral replication, suggesting 
that high expression of DCN induced by active replication of oHEmT-DCN 
contributes to the induction of apoptosis in tumor tissue.  
Hypoxia, a hallmark of the tumor microenvironment, has been 
reported to attenuate replication of oncolytic Ad [10], leading to insufficient 
therapeutic efficacy in hypovascular regions of solid tumors. Therefore, we 
examined the extent of replication of oncolytic Ads in hypoxic tumor regions. 
As shown in Figure 13, high levels of oHEmT and oHEmT-DCN replication 
were observed in hypoxic tumor regions, whereas no detectable accumulation 
of ONYX-015 was observed. The levels of oHEmT and oHEmT-DCN viral 
particles in hypoxic tumor regions were similar to those observed in normoxic 
regions. This finding demonstrates that the HREs upstream of the cancer-
specific promoter can be transactivated by HIF-1Į, which is overexpressed 
under hypoxia, to overcome hypoxia-mediated downregulation of Ad E1A 
expression. Importantly, oHEmT-DCN was distributed over a larger area and 
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more virus was observed under hypoxic conditions compared with oHEmT, 
indicating that DCN-mediated apoptosis facilitates viral dispersion throughout 
desmoplastic pancreatic tumors. 
DCN has been shown to inhibit TGF-ȕDFWLYLW\ZKLFKSOD\VDFULWLFDO
role in aberrant ECM deposition and the subsequent acquisition of resistance 
toward therapeutics in pancreatic tumors. Thus, we next assessed the effect of 
DCN-expressing oncolytic Ad on the ECM in orthotopic pancreatic tumors via 
histological and immunohistochemical staining 0DVVRQ¶V WULFKURPH DQG
picrosirious red staining of pancreatic tumor sections revealed that collagen 
deposition was significantly decreased in oHEmT-DCN-treated tumors 
compared with ONYX-015-treated or oHEmT-treated tumors. As shown in 
Figure 14, tumors treated with oHEmT-DCN contained less collagen compared 
with those treated with PBS, ONYX-015, or oHEmT (**P < 0.01, ***P < 
0.001). Furthermore, oHEmT-DCN-treated tumors exhibited significantly 
attenuated accumulation of major ECM components such as type I collagen, 
type III collagen, elastin, and fibronectin compared with those treated with PBS, 
ONYX-015, or oHEmT. This finding indicates that oncolytic Ad-mediated 
expression of DCN effectively degrades overexpressed ECM components in 
pancreatic tumors (Figure 15; *P < 0.05, **P < 0.01, or ***P < 0.001). Taken 
together, these results indicate that oHEmT-DCN can efficiently degrade ECM, 
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overcome hypoxia-mediated downregulation of Ad E1A expression, and 
exhibit potent antitumor efficacy against highly desmoplastic pancreatic tumors. 
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Figure 12. Histologic, TUNEL, and immunohistochemical staining of 
pancreatic cancer tissue. H & E staining, Ad E1A and PCNA 
immunohistochemical staining, and TUNEL assay results from pancreatic 
cancer tissue. Original magnification: ×100 and ×400. The tumor (T) and 
normal (N) tissues are separated with a dotted line in the oHEmT-DCN-treated 
group. 
 レヱ
 
 
 
Figure 13. Replication of Ad in normoxic and hypoxic tumor regions. Tumor 
sections were stained with anti-Ad E1A Ab to examine viral replication (red). 
HIF-Į Ab were used to visualize hypoxic regions (green). Normoxic and 
hypoxic regions are both visible.  
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Figure 14. 0DVVRQ¶VWULFKURPHDQGpicrosirius red staining of pancreatic cancer 
tissue. Collagen expression was analyzed semi-quantitatively from the resultant 
images. Original magnification: ×100 and ×400. The tumor (T) and normal (N) 
tissues are separated with a dotted line in the oHEmT-DCN-treated group. Data 
are presented as mean ± SD. *P<0.05, **P<0.01, and ***P < 0.001. 
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Figure 15. Expression of ECM components in pancreatic cancer tissue. 
Reduced protein levels of ECM components including collagen type I and III, 
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elastin, and fibronectin were observed in pancreatic cancer tissue treated with 
oHEmT-DCN compared with tissues treated with the other Ads. Semi-
quantitative image analysis was performed to measure the protein levels of type 
I and III collagen, elastin, and fibronectin. Significantly reduced levels of type 
I collagen, type III collagen, elastin, and fibronectin were observed in 
pancreatic cancer tissue treated with oHEmT-DCN than in the tumor tissues 
treated with the control viruses. Original magnification: ×400. Data are 
presented as mean ± SD. *P<0.05, **P<0.01, and ***P < 0.001. 
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Therapeutic efficacy of oHEmT-DCN in patient-derived pancreatic cancer 
organoid cultures 
Although orthotopic tumor models closely emulate tissue-specific 
disease progression of clinical tumors, orthotopic implantation in 
immunodeficient mice does not completely recapitulate tumorigenesis in 
humans because the tumor microenvironments are not equivalent [30]. In this 
regard, 3D organoid culture of patient tumors, an approach that mimics the 
ECM components and complex cell heterogeneity of clinical tumors, is a 
promising model for the evaluation of novel therapeutics [31-34]. To take 
advantage of this model system, pancreatic tumor spheroids derived from 
patient samples were cultured and treated with PBS, ONYX-015, oHEmT, or 
oHEmT-DCN for 6 days. As shown in Figure 16, PBS-treated patient-derived 
pancreatic tumor spheroids were primarily composed of a thick and dense layer 
of ECM components, similar to orthotopic pancreatic tumors (Figure 17). This 
finding indicates that 3D tumor spheroids and orthotopic models both closely 
emulate the desmoplastic attributes of clinical pancreatic tumors. In good 
agreement with our results from the orthotopic pancreatic tumor model, 
oHEmT-DCN induced efficient degradation of major ECM components, 
attenuated proliferation of tumor cells, induced apoptosis in tumor cells, and 
exhibited proficient viral dissemination in patient-derived tumor spheroids 
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(Figure 16-18). Together, these results suggest that oHEmT-DCN induces 
potent antitumor effects by overcoming hypoxia-mediated downregulation of 
Ad E1A expression and desmoplasia in patient-derived tumor spheroids, 
suggesting oHEmT-DCN as a promising candidate for future clinical trials 
targeting aggressive and desmoplastic pancreatic cancer. 
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Figure 16. Histological staining of pancreatic cancer patient-derived 
tumor spheroids. 0DVVRQ¶V WULFKURPH DQG 3LFURVLULXV UHG VWDLQLQJ RI
pancreatic cancer patient-derived tumor spheroids treated with PBS, ONYX-
015, oHEmT, or oHEmT-DCN. Collagen expression was analyzed semi-
quantitatively. Original magnification: ×400. Bars represent mean ± SD. ***P 
< 0.001. 
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Figure 17. Immunohistochemical staining of pancreatic cancer patient-derived 
tumor spheroids for ECM components. Reduced protein levels of various ECM 
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components including collagen type I and III, elastin, and fibronectin were 
observed in primary pancreatic tumor spheroids treated with oHEmT-DCN 
compared with spheroids treated with the other Ads. Type I and III collagen, 
elastin, and fibronectin protein levels were analyzed semi-quantitatively. 
Significantly reduced levels of type I collagen, type III collagen, elastin, and 
fibronectin were observed in primary pancreatic tumor spheroids treated with 
oHEmT-DCN compared with spheroids treated with control viruses. Original 
magnification: ×400.  
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Figure 18. Histologic, TUNEL, and immunohistochemical staining of 
pancreatic cancer patient-derived tumor spheroids. H & E staining, Ad E1A and 
PCNA immunohistochemical staining, and TUNEL assay results from primary 
pancreatic tumor spheroids. Original magnification: ×400. PCNA expression 
and TUNEL assay images were analyzed semi-quantitatively. Bars represent 
mean ± SD. *P<0.05, **P<0.01, and ***P < 0.001. 
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IV. DISCUSSION 
Pancreatic cancer is associated with the worst prognosis of all 
gastrointestinal malignancies [35-37]. The major reasons for these poor 
outcomes are late diagnosis and poor therapeutic efficacy of conventional 
treatments, which are due to the nonspecific symptoms and aggressive tumor 
biology, respectively. Histologically, pancreatic cancer tumors are extremely 
stroma-rich and hypovascular. Indeed, most of the pancreatic tumor mass 
consists of ECM components, such as collagen, desmin, fibronectin, and 
hyaluronic acid [38-40]. Aberrant accumulation of ECM in the tumor 
microenvironment is a major obstacle hindering the success of conventional 
treatments against pancreatic cancer. Gemcitabine, a standard 
chemotherapeutic prescribed for the treatment of pancreatic cancer, can only 
prolong life expectancy by 6 months. The inefficiency of this therapeutic has 
been shown to be due to poor drug permeation into ECM-rich tumors [25, 41].  
Another critical hurdle for the effective treatment of pancreatic cancer 
is hypoxia, which refers to the low partial pressure of oxygen and subsequent 
acidosis that frequently occur in the tumor microenvironment [42]. HIF-ĮD
potent regulator of the homeostatic transcriptional response to hypoxia, is 
significantly overexpressed in pancreatic cancer [43, 44]. Importantly, HIF-Į
stimulates transcription of genes that contain HREs in their promoters. 
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Therefore, transcriptional regulation via a hypoxia- inducible promoter is 
frequently employed to target the hypoxic tumor microenvironment. 
In the present report, we generated two variants of HRE-harboring, 
cancer-selective hybrid promoters (HEmT and HmTE). The levels of transgene 
expression driven by the HEmT promoter and by the HmTE promoter were 
both significantly enhanced under hypoxic conditions, indicating that the HRE 
enhancer enhances promoter activity under hypoxic conditions. Importantly, 
the HEmT promoter induced higher Ad transgene expression than the HmTE 
promoter under both normoxic and hypoxic conditions, demonstrating that the 
level of transcriptional activity of a given hybrid promoter is affected by the 
order in which the promoter components are inserted into the Ad genome 
(Figure 2A and B). Since the HEmT promoter demonstrated superior promoter 
activity to that of the HmTE promoter, we chose to extensively characterize the 
therapeutic efficacy of HEmT-harboring Ads. In addition to exhibiting 
enhanced transcription in hypoxic conditions, HEmT-driven expression of GFP 
was highly cancer-specific. This finding indicates that our novel HEmT hybrid 
promoter is a good candidate for regulating Ad E1A gene expression of 
oncolytic Ad in a manner that endows cancer specificity (Figure 3A and B). 
Oncolytic Ad replicating under the control of the HEmT promoter (oHEmT) 
was highly cytotoxic to cancer cells and exhibited significant replication in a 
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highly cancer-specific manner under both normoxic and hypoxic conditions 
(Figure 4 and 5). These findings are in good agreement with our previous report, 
in which we demonstrated the cancer selectivity of HRE-mediated 
enhancement of oncolytic Ad transgene expression under hypoxic conditions 
[10]. Of note, oHEmT exhibited greater viral replication than oRd19, a control 
oncolytic Ad with the endogenous Ad promoter, in cancer cells. In contrast, no 
evident cytotoxicity was observed in normal cells, implying that the potent and 
cancer-specific killing effect of oHEmT is mediated by efficient and 
preferential replication of oncolytic Ad in cancer cells (Figure 4 and 5).  
Current trends of oncolytic Ad development for clinical applications 
have focused on armed oncolytic Ads expressing anticancer therapeutic genes. 
Several clinical studies have evaluated the efficacy of these Ads against various 
types of cancers [45-47]. In the context of this strategy, we generated oncolytic 
Ad expressing DCN, a potent inducer of tumor cell apoptosis and ECM 
degradation, as a potential candidate for the treatment of desmoplastic 
pancreatic cancer. DCN-expressing oncolytic Ad (oHEmT-DCN) induced a 
dose-dependent increase in DCN expression in a cancer cell-specific manner 
(Figure 6). Furthermore, oHEmT-DCN exhibited dose-dependent cytotoxicity 
in a cancer cell-specific manner that was superior to that of its cognate control 
oncolytic Ad oHEmT, indicating that the dose-dependent increase in DCN 
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achieved with oHEmT-DCN was responsible for the enhanced anticancer effect 
(Figure 8). Moreover, oHEmT-DCN was more highly cytotoxic than oHEmT, 
in a time-dependent manner, further demonstrating that amplification of DCN 
and oncolytic Ad via active viral replication resulted in potent cancer cell 
killing (Figure 7). Of particular interest, only negligible oHEmT-DCN-induced 
DCN expression was detected in normal cells, and no cytotoxicity was observed, 
findings that are in good agreement with a previous report demonstrating that 
DCN-induced apoptosis was cancer-specific [48]. Similar results were 
observed in vivo; that is, oHEmT-DCN exhibited superior antitumor efficacy 
via DCN-mediated induction of apoptosis and active viral replication within 
highly aggressive and desmoplastic orthotopic pancreatic tumor tissue 
compared to its cognate control oHEmT (Figure 9-12). Furthermore, normal 
tissue adjacent to the tumor was not affected by oHEmT-DCN. These findings 
are in good agreement with previous reports demonstrating that DCN induces 
cancer-selective apoptosis but is not detrimental to normal cells, providing 
further support for the idea that low level expression level of Ad-mediated DCN 
in normal cells is not harmful [14, 26].  
The ECM is a critical hurdle complicating oncolytic Ad-mediated gene 
therapy for the treatment of pancreatic cancer, since the coarse and dense ECM 
prevents penetration and dispersion of Ad into tumor tissue. TGF-ȕ LVDkey 
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profibrotic cytokine that induces ECM accumulation in pancreatic tumors by 
inhibiting proteolytic enzymes. Decorin harbors a high-affinity binding site for 
TGF-ȕWKXVELQGLQJRIGHFRULQWR7*)-ȕQHXWUDOL]HVLWVELRORJLFDO activity [13]. 
We found that TGF-ȕSURWHLQOHYHOZDVsignificantly reduced by oHEmT-DCN 
in orthotopic pancreatic tumor tissue, supporting the idea that decorin is a 
natural inhibitor of TGF-ȕ Figure 11). Importantly, DCN-mediated 
suppression of TGF-ȕfollowing oHEmT-DCN treatment was positively 
correlated with attenuation in the expression levels of major ECM components, 
such as collagen types I & III, fibronectin, and elastin, indicating that oncolytic 
Ad-mediated expression of DCN can effectively degrade ECM components in 
tumor tissue via downregulation of the profibrotic cytokine TGF-ȕ(Figure 11, 
14, and 15)In addition, the DCN expression level and extent of ECM 
component degradation were both positively correlated with Ad dispersion and 
accumulation within pancreatic tumors. These findings are in good agreement 
with a previous report, demonstrating that DCN enhances Ad penetration and 
distribution within solid tumors via ECM degradation [14]. Alternatively, 
induction of apoptosis has been reported to enhance viral dispersion within 
solid tumors by transferring Ad progeny virus to neighboring tumor cells via 
apoptotic bodies and attenuating intratumoral interstitial pressure [49]. In good 
agreement with this report, oHEmT-DCN potently induced apoptosis in tumor 
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tissue; furthermore, this effect was positively correlated with the extent of viral 
dispersion and replication within solid tumors. Together, these results 
demonstrate that oHEmT-DCN potently induces apoptosis and efficient 
degradation of ECM components, thereby resulting in high levels of viral 
dissemination and active replication within orthotopic pancreatic tumor tissue.
Hypovascularization within solid tumors has been demonstrated to 
suppress replication of oncolytic Ad, resulting in poor and uneven viral 
distribution in tumor tissue [11, 12]. The HRE enhancer, which binds to 
overexpressed HIF-1Į under hypoxic conditions and induces transactivation of 
its downstream promoters, has been frequently employed to achieve tumor 
selectivity. Oncolytic Ad replicating under the control of our novel HRE-
harboring cancer-specific hybrid promoter HEmT (oHEmT) showed enhanced 
viral replication under hypoxic conditions compared with normoxic conditions. 
Thus, our strategy was able to overcome hypoxia-induced downregulation of 
Ad E1A expression both in vitro and in vivo (Figure 5 and 13). Furthermore, 
the level of Ad E1A expression achieved with oHEmT-DCN was markedly 
higher than that achieved with ONYX-015 or its cognate control, oHEmT, in 
hypoxic tumor regions. Together, these results demonstrate that the 
combination of a hypoxia-responsive promoter with intratumoral expression of 
DCN can yield enhanced viral replication and dispersion of oHEmT-DCN in 
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hypovascular tumor regions, as well as in normoxic regions of ECM-rich 
pancreatic tumors.  
3D organoid culture of primary patient tumors can provide a more 
accurate representation of the clinical tumor microenvironment compared with 
orthotopic xenograft models. Furthermore, 3D patient tumor spheroids retain 
their heterogeneous tumor cell populations as well as the complex network of 
cell-cell and cell-matrix interactions exhibited in clinical tumors, making this 
model a promising candidate for evaluating the penetration and action of novel 
therapeutics [50, 51]. In the present study, both orthotopic pancreatic tumors 
and tumor spheroids derived from patients with pancreatic cancer exhibited 
aberrantly high deposition of ECM components. These characteristics closely 
emulate the desmoplastic attributes of clinical pancreatic cancer described in 
previous literature (Figure 14, and 16). In both orthotopic tumors and primary 
patient spheroids, oHEmT-DCN effectively induced tumor cell apoptosis, ECM 
degradation, and dispersion of Ad in both normoxic and hypoxic tumor regions, 
leading to a potent tumoricidal effect. 
In summary, we demonstrated that a novel DCN-expressing oncolytic 
Ad, oHEmT-DCN, can potently inhibit tumor growth through a multifunctional 
process. In this process, degradation of ECM, hypoxia responsiveness, and 
induction of apoptosis facilitate dispersion and active replication of oncolytic 
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Ad in both normoxic and hypoxic regions of desmoplastic pancreatic tumors 
that closely emulate clinical tumors. These findings suggest oHEmT-DCN as a 
promising therapeutic candidate for future clinical trials against aggressive 
pancreatic cancer. 
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V. CONCLUSION 
In this study, our results demonstrate that oHEmT-DCN can potently 
inhibit tumor growth through a multifunctional process. In this process, ECM 
degradation, hypoxia responsiveness, and induction of apoptosis facilitate the 
permeation and replication of oncolytic Ad in both normoxic and hypoxic 
regions of desmoplastic pancreatic tumors. Our results indicate that our novel 
oncolytic Ad, oHEmT-DCN, is a promising therapeutic agent for the treatment 
of aggressive and highly desmoplastic pancreatic cancer. 
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ABSTRACT (in Korean) 
 
㫛㟧 ⹎㎎䢮ἓ㦚 Ṳ㍶䞮⓪ ◆䆪Ⰶ ⹲䡚 㫛㟧 䔏㧊㩗 ㌊㌗ 㞚
◆⏎⹪㧊⩂㓺㦮 Ṳ⹲ ⹥ 䀢㧻㞪 ⳾◎㠦㍲㦮 䟃㫛㟧 䣾ὒ 䘟Ṗ 
 
<㰖☚ᾦ㑮 㾲 㧎 䢣> 
 
㡆㎎╖䞯ᾦ ╖䞯㤦 
⋮⏎Ⲫ❪䃒䡧☯ὒ㩫 
 
Ⰲ 㡆 
 
2013⎚ Ⱖ ⹲䚲♲ ῃṖ 㞪 ❇⪳䐋Ἒ 㧦⬢㠦 ➆⯊Ⳋ, 䀢㧻㞪㦖 
䞲ῃ㧎 㞪 ㌂ⰳ㤦㧎㦮 5㥚⪲ 㫆㌂♲ 㞪㫛 㭧 5⎚ ㌳㫊㥾㧊 Ṗ㧻 
⌄㦖 5%, 㭧㞯㌳㫊₆Ṛ㦖 5 Ṳ㤪㠦 ⿞ὒ䞲 Ṗ㧻 䂮ⳛ㩗 
㫛㟧㰞䢮㧊┺. 䀢㧻㞪 䢮㧦㦮 90% 㩫☚⓪ 㧊⹎ ⁒䂮㩗 㑮㑶㦚 
㔲䟟䞶 㑮 㠜⓪ ㌗䌲㠦㍲ ⹲ἂ♮㠊 㧎㼊 㞪 㭧 㡞䤚Ṗ Ṗ㧻 ⿞⨟䞲 
ộ㦒⪲ ⽊ἶ♮㠞┺. ⡦䞲 䀢㧻㞪 䢮㧦㦮 䟃㞪㩲 ⹮㦧⮶㦖 20% 
⌊㣎㠦 ⿞ὒ䞶 ㈦ 㞚┞⧒ 㫆₆㠦 䟃㞪㩲 ⌊㎇㧊 ⹲㌳䞮⓪ ộ㦒⪲ 
㞢⩺㪎 㧞┺. ἆ䞿㫆㰗㯳㔳 ⹮㦧(desmoplasia)㧊 䢲⹲䞮Ợ 
㧒㠊⋮⓪ 䀢㧻㞪 㫆㰗㦖 㫆㰗 ⌊ 㯳Ṗ♲ 㩖㌆㏢ 㫆Ịὒ ὒ☚䞮Ợ 
⿚䙂♲ ㎎䙂㣎₆㰞(extracellular matrix)⪲ 㧎䟊 㫛㟧㦮 㞛㎇☚Ṗ 
䋂Ợ 㯳Ṗ♶ ㈦ 㞚┞⧒ 㟓ⶒ㦮 䂾䒂 ⹥ 䢫㌆㧊 㩖䟊♮ἶ 㧊⩂䞲 
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䀢㧻㞪 㫆㰗㦮 ☛䔏䞲 䔏㎇㦖 䟃㞪 䂮⬢㩲㦮 䂮⬢䣾ὒ⯒ 
Ṧ㏢㔲䋺⓪ 㤦㧎㦒⪲ 㧧㣿䞲┺. ⁎⩂⸖⪲ 㧊⩂䞲 䀢㧻㞪㦮 㫛㟧 
⹎㎎䢮ἓ㦚 䚲㩗䞶 㑮 㧞⓪ ㌞⪲㤊 䕾⩂┺㧚㦮 䀢㧻㞪 䂮⬢㩲㦮 
Ṳ⹲㧊 㩞㔺䧞 㣪ῂ♮⓪ 㔺㩫㧊┺. 
➆⧒㍲ ⽎ 㡆ῂ㠦㍲⓪, 㫛㟧 䔏㧊㩗 ㌊㌗ 㞚◆⏎⹪㧊⩂㓺㦮 
㩖㌆㏢ 㫆Ị㠦㍲㦮 ⽋㩲⓻㦚 㯳Ṗ㔲䋺₆ 㥚䟊, 㫛㟧 ㌊㌗ 
㞚◆⏎⹪㧊⩂㓺㧎 Rd19-k35 㠦 㫛㟧 ㍶䌳㎇㦚 ⏨㧊ἶ 㩖㌆㏢ 
㫆Ị㠦㍲ ⹪㧊⩂㓺㦮 ⽋㩲⯒ 㫆㩞䞶 㑮 㧞⓪ HmTE 㢖 HEmT 
䝚⪲⳾䎆⯒ ☚㧛䞮㡂 oHmTE(HmTE-Rd19-k35)㢖 oHEmT(HEmT-Rd19-
k35)⯒ 㩲㧧䞮㡖┺. 䀢㧻㞪 ㎎䙂㭒㠦㍲ 㩲㧧♲ oHmTE 㢖 oHEmT 㦮 
㞪㎎䙂 ㌊㌗⓻ ⹥ ⹪㧊⩂㓺 㯳㔳⓻㦚 Ỗ㯳䞮㡂, oHmTE 㠦 ゚䟊 
oHEmT Ṗ 㤆㑮䞲 䝚⪲⳾䎆 䢲㎇㦚 ⋮䌖⌊⓪ ộ㦚 䢫㧎䞮㡖┺. 
㧊⩂䞲 ἆὒ⯒ ⹪䌫㦒⪲, oHEmT ⹪㧊⩂㓺㠦 ㎎䙂ἶ㌂⯒ 㥶☚䞮ἶ 
㎎䙂㣎₆㰞㦚 ⿚䟊䞶 㑮 㧞⓪ ◆䆪Ⰶ(DCN)㥶㩚㧦⯒ ㌓㧛䞮㡂 
oHEmT-DCN㦚 㩲㧧䞮ἶ 㧊⯒ 㧊㣿䞮㡂 䀢㧻㞪 ☯㏢㧊㔳 ☯ⶒ⳾◎ ⹥ 
䀢㧻㞪 䢮㧦 㥶⧮ 㫛㟧㫆㰗㠦㍲ 䟃㫛㟧 䣾ὒ⯒ 䢫㧎䞮㡖┺. oHEmT-
DCN ⯒ 䒂㡂䞲 ⁎⭏㠦㍲ 䡚㨂 㔲䕦♮ἶ 㧞⓪ 㫛㟧 䔏㧊㩗 ㌊㌗ 
㞚◆⏎⹪㧊⩂㓺㧎 ONYX-015 ⡦⓪ ╖㫆ῆ㧎 oHEmT⯒ 䒂㡂䞲 ⁎⭏㠦 
゚䟊 䡚㩖䧞 䟻㌗♲ 䟃㫛㟧 䣾ὒṖ ⋮䌖⋾㦚 䢫㧎䞮㡖┺. ㈦Ⱒ 
㞚┞⧒ 䀢㧻㞪 㫆㰗㠦㍲ HEmT 䝚⪲⳾䎆㠦 㦮䟊 ⹪㧊⩂㓺Ṗ 㩖㌆㏢ 
䢮ἓ㦚 䣾ὒ㩗㦒⪲ 䚲㩗䞮㡂 㩖㌆㏢ 㫆Ị㠦㍲㦮 ⹪㧊⩂㓺 
⽋㩲㩖䞮Ṗ Ṳ㍶♾㦚 䢫㧎䞮㡖ἶ, 㫛㟧㫆㰗 ⌊㠦㍲ oHEmT-DCN 㠦 
㦮䞲 䂮⬢㥶㩚㧦 DCN㦮 ⹲䡚 㯳Ṗ, TGF-ഒ㦮 ⹲䡚 Ṧ㏢, ⹪㧊⩂㓺 
⿚䙂 ⹥ ⽋㩲 㯳Ṗ, 䀢㧻㞪 㫆㰗 ⌊㦮 ㎎䙂㣎₆㰞 ⿚䟊 㯳Ṗ, 
⁎Ⰲἶ 㫛㟧㫆㰗 䔏㧊㩗 ㎎䙂ἶ㌂㦮 㯳Ṗ ❇㦚 䐋䟊 ἆὒ㩗㦒⪲ 
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㤆㑮䞲 䟃㫛㟧 䣾ὒṖ 㥶☚♾㦚 䢫㧎䞮㡖┺. ➆⧒㍲ ◆䆪Ⰶ㦚 
⹲䡚䞮⓪ 㫛㟧 ㍶䌳㩗 ㌊㌗ 㞚◆⏎⹪㧊⩂㓺⓪ 㫛㟧 ⹎㎎䢮ἓ㦮 
㩖㌆㏢ 㫆Ị ⹥ ㎎䙂㣎₆㰞㦚 䣾ὒ㩗㦒⪲ 䚲㩗䞮ἶ 㯳╖♲ 䟃㫛㟧 
䣾ὒ⯒ 㥶☚䞮⸖⪲ 㞞㩚䞮ἶ 䣾ὒ㩗㧎 䀢㧻㞪 䂮⬢㩲⪲ 㩗㣿♶ 㑮 
㧞㦚 ộ㦒⪲ ㌂⬢♲┺. 
 
䟋㕂♮⓪ Ⱖ: 㫛㟧 䔏㧊㩗 ㌊㌗ 㞚◆⏎⹪㧊⩂㓺; 䀢㧻㞪; ◆䆪Ⰶ; 
㩖㌆㏢; ἆ䞿㫆㰗㯳㔳; 㫛㟧 䔏㧊㩗 䝚⪲⳾䎆; ㎎䙂㣎₆㰞 
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